摘要:
A construct of the structure F—S1-S2 where: F—S1 is an aminoalkylglycoside where F is α-D-galactopyranosyl-(1→4)-B-D-galactopyranosyl-(1→4)-β-D-glucopyranoside and S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl or 5-aminopentyl; S2 is —CO(CH2)2CO—, —CO(CH2)3CO—, —CO(CH2)4CO— or —CO(CH2)5CO—; and L is phosphatidylethanolamine.
摘要:
Peptide-lipid constructs of the structure L-S-F are disclosed, where F is a peptide, S is a spacer covalently linking F to L via an oligomer of ethylene glycol, and L is a diacyl- or dialkyl-glyccrolipid (including glyccrophospholipids). The spacer ideally has 6 to 14 ethylene glycol repeats, corresponding to PEG with a molecular weight of approximately 250 to 600. Also disclosed is a method of detecting reactive antibodies in serum by contacting serum with cells modified to incorporate a peptide-lipid construct, where the peptide is an epitope of the antibody, and determining the degree of agglutination of the cells.
摘要:
Method of incorporating a water soluble construct of the structure L-S-F into the lipid bi-layer of cells by contacting a suspension of the cells with a solution of the construct at a concentration and for a time and temperature sufficient to allow the construct to insert into the lipid bi-layer. In the structure L-S-F, F is a peptide, S is a spacer containing an oligomer of ethylene glycol covalently linking F to L and the number of ethylene oxide repeats in the oligomer of ethylene glycol is 6 to 14, and L is a phosphatidylethanolamine.
摘要:
Cells incorporating a synthetic molecule construct of the structure F—S1—S2-L where: F—S1 is an aminoalkylglycoside where F is a mono-, di-, tri- or oligo-saccharide and S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl; S2 is —CO(CH2)2CO—, —CO(CH2)3CO—, —CO(CH2)4CO— or —CO(CH2)5CO—; and L is phosphatidylethanolamine.
摘要:
Synthetic molecule construct of the structure F-S1-S2-L where F-S1 is an aminoalkylglycoside and S2-L is a dicarboxylated, e.g. adipylated, phosphatidylethanolamide are disclosed. The two terminal sugars of the aminoalkylglycoside (Galα1-3Galβ-) are the two terminal sugars of the Galili antigen.
摘要:
A construct of the structure F—S1-S2 where: F—S1 is an aminoalkylglycoside where F is α-D-galactopyranosyl-(1→4)-β-D-galactopyranosyl-(1→4)-β-D-glucopyranoside and S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl or 5-aminopentyl; S2 is —CO(CH2)2CO—, —CO(CH2)3CO—, —CO(CH2)4CO— or —CO(CH2)5CO—; and L is phosphatidylethanolamine.
摘要:
Synthetic molecule construct of the structure F-S1-S2-L where F—S1 is an aminoalkylglycoside and S2-L is a dicarboxylated, e.g. adipylated, phosphatidylethanolamide are disclosed. The two terminal sugars of the aminoalkylglycoside (Galα1-3Galβ-) are the two terminal sugars of the Galili antigen.
摘要:
Cells incorporating a synthetic molecule construct of the structure F—S1—S2-L where: F—S1 is an aminoalkylglycoside where F is a mono-, di-, tri- or oligo-saccharide and S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl; S2 is —CO(CH2)2CO—, —CO(CH2)3CO—, —CO(CH2)4CO— or —CO(CH2)5CO—; and L is phosphatidylethanolamine.
摘要:
Cells incorporating a synthetic molecule construct of the structure F—S1-S2-L where: F—S1 is an aminoalkylglycoside where F is a mono-, di-, tri- or oligo-saccharide and S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl; S2 is —CO(CH2)2CO—, —CO(CH2)3CO—, —CO(CH2)4CO— or —CO(CH2)5CO—; and L is phosphatidylethanolamine.